Regencell Bioscience soars as stock split takes effect

While shares of Regencell Bioscience (RGC) are off today’s lows, the stock is still up 228%, or $36.35, to $52.30 in afternoon trading. Regencell effected a 38-for-one forward stock split today, paid in the form of a stock bonus that it announced on June 2. Regencell, which is yet to report any revenue, is a bioscience company that focuses on research, development and commercialization of “Traditional Chinese Medicine” for the treatment of neurocognitive disorders and degeneration, specifically attention deficit hyperactivity disorder and autism spectrum disorder. “Our goal is to save and improve the lives of the patients, their families and caregivers and become a market leader for natural and holistic treatments for neurological disorders globally,” the company explains. The shares are up 64,000% this year, according to Bloomberg.